1-(5-Methyl-1,3-oxazol-2-yl)ethan-1-amine | 1017179-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(5-Methyl-1,3-oxazol-2-yl)ethan-1-amine
• 英文别名: 1-(5-methyl-1,3-oxazol-2-yl)ethanamine
• CAS: 1017179-33-7
• 化学式: C₆H₁₀N₂O
• mdl: MFCD09884299
• 分子量: 126.16
• InChiKey: BCZCRYDWZCGWIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• COMPOUNDS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
  申请人：University Of Southern California, USC Stevens

  公开号：EP3935944A1

  公开（公告）日：2022-01-12

  Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular diorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases.

  本发明公开了用于治疗血管紧张素相关疾病和紊乱（包括心血管疾病、代谢性疾病、胃肠道疾病、肾脏疾病、炎症/自身免疫性疾病、神经系统疾病、骨髓疾病和癌症）的小分子非肽化合物、方法和组合物。特别是，本发明提供了用于治疗代谢性疾病和紊乱的化合物、方法和组合物，如糖尿病、糖尿病相关心血管疾病、糖尿病相关皮肤溃疡、糖尿病相关高血压和糖尿病相关眼科疾病。
• Triazole pyridyl compounds as agonists of the APJ receptor
  申请人：AMGEN INC.

  公开号：US10689367B2

  公开（公告）日：2020-06-23

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein.

  式 I 和式 II 的化合物、其药学上可接受的盐、前述任何化合物的立体异构体或其混合物是 APJ 受体的激动剂，可用于治疗心血管疾病和其他疾病。式 I 和式 II 的化合物具有本文提供的变量定义的结构。
• TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
  申请人：Amgen Inc.

  公开号：EP3541803B1

  公开（公告）日：2020-12-23
• [EN] METHODS FOR TREATING MYELOSUPPRESSION<br/>[FR] MÉTHODES DE TRAITEMENT DE LA MYÉLOSUPPRESSION
  申请人：GAFFNEY KEVIN J

  公开号：WO2019027890A1

  公开（公告）日：2019-02-07

  Methods are disclosed for treating myelosuppression by administering a compound having the general formula 1 or a pharmaceutically acceptable salt thereof, as defined herein